MX360181B - Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions. - Google Patents

Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions.

Info

Publication number
MX360181B
MX360181B MX2010005476A MX2010005476A MX360181B MX 360181 B MX360181 B MX 360181B MX 2010005476 A MX2010005476 A MX 2010005476A MX 2010005476 A MX2010005476 A MX 2010005476A MX 360181 B MX360181 B MX 360181B
Authority
MX
Mexico
Prior art keywords
eag1
protein
detecting
detection
cancer
Prior art date
Application number
MX2010005476A
Other languages
Spanish (es)
Other versions
MX2010005476A (en
Inventor
Stühmer Walter
A Pardo Luis
Javier Camacho Arroyo Francisco
Sharon Ortiz Arce Cindy
Del Rosario SOLÍS PANCOÁTL María
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N filed Critical Centro De Investig Y De Estudios Avanzados Del I P N
Priority to MX2010005476A priority Critical patent/MX360181B/en
Publication of MX2010005476A publication Critical patent/MX2010005476A/en
Publication of MX360181B publication Critical patent/MX360181B/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention describes a method for the early detection of cervicouterine cancer (CuCa) by detecting the human protein Eag1 with specific antibodies. The Eag1 protein is differentially expressed in cervical tissue and in close association with the stage development of the disease, thereby cancer being detected in early phases, thus the aforementioned method may be useful as an adjuvant in the opportune detection of CuCa. In addition, the inventive method intends to reduce the percentage of false positive or negative obtained in the cytological detection test (Papanicolaou) and may increase the detection sensibility in the tests currently used for the diagnosis of CuCa.
MX2010005476A 2010-05-19 2010-05-19 Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions. MX360181B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2010005476A MX360181B (en) 2010-05-19 2010-05-19 Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010005476A MX360181B (en) 2010-05-19 2010-05-19 Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions.

Publications (2)

Publication Number Publication Date
MX2010005476A MX2010005476A (en) 2011-11-18
MX360181B true MX360181B (en) 2018-10-16

Family

ID=45804149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005476A MX360181B (en) 2010-05-19 2010-05-19 Diagnosis method for the early detection of cervicouterine cancer by detecting the eag1 protein as a marker of cervical intraepithelial lesions.

Country Status (1)

Country Link
MX (1) MX360181B (en)

Also Published As

Publication number Publication date
MX2010005476A (en) 2011-11-18

Similar Documents

Publication Publication Date Title
WO2011015602A3 (en) Lung cancer biomarkers
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
MX2018004067A (en) Quencher containing water soluble polymer-conjugated nanomaterial and use thereof.
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
NZ598194A (en) Anti-cmet antibody and its use for the detection and the diagnosis of cancer
BR112013003391A2 (en) pancreatic cancer biomarkers and their uses
EP4335932A3 (en) Methods of monitoring conditions by sequence analysis
JP2014144959A5 (en)
WO2014074835A3 (en) Antibody compositions and immunoassay methods to detect isoforms of anti-mullerian hormone
WO2012017466A8 (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
WO2010136163A8 (en) Secernin-1 as a marker for cancer
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
PE20141565A1 (en) METHODS TO DETECT HUMAN PAPILLOMAVIRUS AND PROVIDE PROGNOSIS FOR SCAMOUS CELL CARCINOMA OF THE HEAD AND NECK
WO2010099137A3 (en) In situ methods for monitoring the emt status of tumor cells in vivo
MX359376B (en) Method and kit for determination of free copper in serum.
BR112014031957A2 (en) bag3 as biochemical serum and tissue marker
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2011109112A3 (en) Method of detecting tau protein and tau fragments in serum
BR112016002709A2 (en) keratins as biomarkers for cervical cancer and survival
WO2012071405A3 (en) Kits and assays for amplification of expressed salmonella genes from blood
AU2013231230A8 (en) Method for selecting or identifying a subject for V1B antagonist therapy

Legal Events

Date Code Title Description
FG Grant or registration